Guardant Health and ConcertAI have partnered to create a first-of-its-kind multi-modal real-world data (RWD) solution, integrating comprehensive patient EMR data with genomic and epigenomic tumor profiling. By combining Guardant’s liquid biopsy technology with ConcertAI’s AI-driven analytics, the collaboration aims to provide biopharma companies with deeper insights into cancer biology, resistance mechanisms, and tumor evolution across the cancer care continuum. This innovative approach includes unique methylation data from Guardant’s platform and is expected to enhance cancer therapy development, clinical trial design, and precision medicine strategies. Financial terms of the agreement remain undisclosed.
Trending
- Private equity owns less than 4% of U.S. hospitals, study finds (Medical Xpress)
- FIT Misses More CRCs in Women; Could Sex-Specific Thresholds Help? (HCP Live)
- Greg O’Grady: The Surgeon Who Left Surgery to Map the Stomach (Gut Health Times)
- GI Practices Lose More on Second Procedures Than Any Other Specialty, Jiro Health Benchmark Finds (PR Newswire)
- Throne Announces First Clinical Validation Study, Demonstrating Its AI-Powered Stool Classification Performs Comparably to Board-Certified Gastroenterologists (Business Wire)
- Blood-Based Colorectal Cancer Screening Averts More Deaths Than Stool Tests, Modeling Shows (Clinical Lab Products)
- For Better or Worse, Monitored Anesthesia Care Is Now the Default in GI Endoscopy (GI & Endoscopy News)
- AI ‘may offer an efficient way’ to detect colorectal neoplasia, but more research needed (Healio)
